Siwen Hu-Lieskovan, MD
Internal Medicine · Los Angeles, CANPI 1578864864
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $46,485 of the $68,178 with a category attached, or 68.2%. 11 manufacturers reported payments, led by Amgen at 39.1% of the total. Reporting peaked in 2023 at $23,952 and has fallen 66.7% since, to $7,965 in 2025. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 72 payments — averaging $946.91 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$27K
- Regeneron$15K
- Pfizer$7K
- Ascendis Pharma Endocrinology Inc$6K
- Immunocore Limited$6K
- Astellas Pharma Inc$5K
- plus $3K from 5 others
Across 213 payments — averaging $13,552 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.2M
- E.r. Squibb & Sons, L.L.C.$394K
- Boehringer Ingelheim$359K
- Regeneron$309K
- Pfizer$289K
- Immunocore Limited$169K
- plus $124K from 3 others
What the payments were for
- Consulting fees$46,48568%
- Speaking & faculty fees$11,94618%
- Travel & lodging$7,47211%
- Food & beverage$2,2753%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen | 26 | $26,666 |
| Regeneron | 17 | $15,006 |
| Pfizer | 7 | $6,850 |
| Ascendis Pharma Endocrinology Inc | 6 | $5,909 |
| Immunocore Limited | 9 | $5,539 |
| Astellas Pharma Inc | 1 | $4,960 |
| E.r. Squibb & Sons, L.L.C. | 2 | $1,838 |
| Delcath Systems | 1 | $1,050 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $125 |
| Biontech SE | 1 | $118 |
| Taiho Oncology, Inc. | 1 | $118 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LIBTAYO$14,582
- KIMMTRAK$5,281
- Hepzato Kit$1,050
- IMBRUVICA$125
- Lonsurf$118
How this compares
$68,178 in reported general payments places this provider in the 95th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MekinistTrametinib Dimethyl Sulfoxide | 13 | $116,664 |
| Prednisone | 47 | $437 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 14 | $122 |
| Levothyroxine Sodium | 22 | $61 |
| Trazodone Hcl | 18 | $46 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Los Angeles
- William HardyLos Angeles$704K
- Soha DolatabadiLos Angeles$458K
- Matthew HerrmannLos Angeles$384K
- Koppany VisnyeiLos Angeles$287K
- Jaime BetancourtLos Angeles$286K
- William KingLos Angeles$227K
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.